Psyence Biomedical Ltd.
PBM
$5.21
-$0.445-7.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.76% | 46.76% | 382.13% | 147.81% | -0.93% |
| Depreciation & Amortization | 1,100.00% | 1,100.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.28% | 34.28% | 556.70% | 32.09% | -50.28% |
| Operating Income | -34.28% | -34.28% | -556.70% | -32.09% | 50.28% |
| Income Before Tax | 96.07% | 96.07% | 145.69% | 284.30% | -1,835.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.07% | 96.07% | 145.69% | 284.30% | -1,835.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.07% | 96.07% | 145.69% | 284.30% | -1,835.19% |
| EBIT | -34.28% | -34.28% | -556.70% | -32.09% | 50.28% |
| EBITDA | -34.09% | -34.11% | -- | -- | -- |
| EPS Basic | 99.75% | 99.75% | 129.47% | -- | -- |
| Normalized Basic EPS | 83.98% | 83.98% | -200.89% | -- | -- |
| EPS Diluted | 99.75% | 99.75% | 129.40% | -- | -- |
| Normalized Diluted EPS | 83.98% | 83.98% | -200.82% | -- | -- |
| Average Basic Shares Outstanding | 1,494.20% | 1,494.20% | 54.91% | -- | -- |
| Average Diluted Shares Outstanding | 1,494.20% | 1,494.20% | 54.91% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |